The majority of attendees are actively involved in breath research and gave a variety of engaging presentations.


Doug Hastie Syft Technologies CEO

Doug Hastie

BE(Hons), MBA


Managing Director

Doug completed his honours degree in Engineering from the University of Auckland in 1988 and an MBA from Yale University in 2000. He completed Engineering projects on the Channel Tunnel in the UK, Disneyland Paris and various Burger Kings in New Zealand.

He worked for Goldman, Sachs & Co. in New York and in Private Equity for Stonebridge Partners in New York. Since returning to New Zealand Doug created the Chanui Tea & Biscuit Brand.

Since joining Syft in 2012, Doug has been instrumental in commercialising the fantastic technology developed here at Syft and putting us on the map.

The advantages and challenges of looking for volatile biomarkers was discussed at length.


Daniel Milligan Syft Technologies Director - Engineering and Development

Dr. Daniel Milligan

BSc(Hons), PhD


Director - Engineering and Development

Daniel started his career as a kineticist; his PhD was studying ion-molecule chemistry and SIFT-MS with Professor McEwan, after which he did a post-doctoral fellowship at CalTech/NASA/JPL in Pasadena, California. He returned to SIFT-MS and Syft via a University of Canterbury postdoctoral fellowship in 2003.

Daniel’s interests have always centered around instrumentation and he now heads the Development and Engineering efforts of Syft. His path to this role has not always been direct however going by way of applications development, support, and a stint as VP Technology for Syft in Cleveland, Ohio.

Syft’s CEO, Doug Hastie, and Director of Engineering and Development, Dr Daniel Milligan, were delighted to represent Syft at the recent Selected Ion Flow Tube Mass Spectrometry (SIFT-MS) Biomarker Seminar held near London, UK, in mid-October. Co-organized by Professors David Smith and Patrik Španěl – the originators of SIFT-MS – and Anatune, the seminar attracted about 25 attendees from the UK and Europe. The majority of attendees are actively involved in breath research and gave a variety of engaging presentations.

The advantages and challenges of looking for volatile biomarkers was discussed at length. Professor Smith gave a number of examples about the process used to qualify biomarkers.

The unique ability of SIFT-MS to rapidly measure volatile biomarkers directly from breath in the presence of a wide range of other compounds was highlighted. This is derived from the instantly switchable reagent (or precursor) ions and ultra-soft ionization.

Dr Clare Turner highlighted the need to analyze large numbers of samples to be able to really qualify these biomarkers. Improving and standardizing sample collection, storage, and treatment will be a big part of this, as will instrumentation. Advances in automation of SIFT-MS that were presented by Dr Mark Perkins support these aspirations.

img_0361

 

SIFT-MS has great potential in biomarker research. To learn more about its benefits, browse our website or contact us today!

Contact us